BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

229 related articles for article (PubMed ID: 27241015)

  • 1. Safer scoring? Cryptomarkets, social supply and drug market violence.
    Barratt MJ; Ferris JA; Winstock AR
    Int J Drug Policy; 2016 Sep; 35():24-31. PubMed ID: 27241015
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Hidden wholesale: The drug diffusing capacity of online drug cryptomarkets.
    Aldridge J; Décary-Hétu D
    Int J Drug Policy; 2016 Sep; 35():7-15. PubMed ID: 27260863
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The transparency paradox. Building trust, resolving disputes and optimising logistics on conventional and online drugs markets.
    Tzanetakis M; Kamphausen G; Werse B; von Laufenberg R
    Int J Drug Policy; 2016 Sep; 35():58-68. PubMed ID: 26809972
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Comparing cryptomarkets for drugs. A characterisation of sellers and buyers over time.
    Tzanetakis M
    Int J Drug Policy; 2018 Jun; 56():176-186. PubMed ID: 29449105
    [TBL] [Abstract][Full Text] [Related]  

  • 5. 'What if you live on top of a bakery and you like cakes?'-Drug use and harm trajectories before, during and after the emergence of Silk Road.
    Barratt MJ; Lenton S; Maddox A; Allen M
    Int J Drug Policy; 2016 Sep; 35():50-7. PubMed ID: 27157539
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Delivery dilemmas: How drug cryptomarket users identify and seek to reduce their risk of detection by law enforcement.
    Aldridge J; Askew R
    Int J Drug Policy; 2017 Mar; 41():101-109. PubMed ID: 28089207
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Forensic drug intelligence and the rise of cryptomarkets. Part II: Combination of data from the physical and virtual markets.
    Morelato M; Broséus J; De Grazia A; Tahtouh M; Esseiva P; Roux C
    Forensic Sci Int; 2018 Jul; 288():201-210. PubMed ID: 29763810
    [TBL] [Abstract][Full Text] [Related]  

  • 8. New psychoactive substances (NPS) on cryptomarket fora: An exploratory study of characteristics of forum activity between NPS buyers and vendors.
    Van Hout MC; Hearne E
    Int J Drug Policy; 2017 Feb; 40():102-110. PubMed ID: 28027812
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Characterising dark net marketplace purchasers in a sample of regular psychostimulant users.
    Van Buskirk J; Roxburgh A; Bruno R; Naicker S; Lenton S; Sutherland R; Whittaker E; Sindicich N; Matthews A; Butler K; Burns L
    Int J Drug Policy; 2016 Sep; 35():32-7. PubMed ID: 26872846
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Going international? Risk taking by cryptomarket drug vendors.
    Décary-Hétu D; Paquet-Clouston M; Aldridge J
    Int J Drug Policy; 2016 Sep; 35():69-76. PubMed ID: 27453145
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Should we smoke it for you as well? An ethnographic analysis of a drug cryptomarket environment.
    Kowalski M; Hooker C; Barratt MJ
    Int J Drug Policy; 2019 Nov; 73():245-254. PubMed ID: 31054880
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The relationship between cryptomarket drug purchase, social networks and adverse drug events: A cross-sectional study.
    Coney L; Peacock A; Malm A; Munksgaard R; Aldridge J; Ferris JA; Maier LJ; Winstock AR; Barratt MJ
    Int J Drug Policy; 2024 Jan; 123():104258. PubMed ID: 38056221
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Silicon to syringe: Cryptomarkets and disruptive innovation in opioid supply chains.
    Gilbert M; Dasgupta N
    Int J Drug Policy; 2017 Aug; 46():160-167. PubMed ID: 28735772
    [TBL] [Abstract][Full Text] [Related]  

  • 14. #Drugsforsale: An exploration of the use of social media and encrypted messaging apps to supply and access drugs.
    Moyle L; Childs A; Coomber R; Barratt MJ
    Int J Drug Policy; 2019 Jan; 63():101-110. PubMed ID: 30530252
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Assessing market competition and vendors' size and scope on AlphaBay.
    Paquet-Clouston M; Décary-Hétu D; Morselli C
    Int J Drug Policy; 2018 Apr; 54():87-98. PubMed ID: 29414490
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Offline constraints in online drug marketplaces: An exploratory analysis of a cryptomarket trade network.
    Norbutas L
    Int J Drug Policy; 2018 Jun; 56():92-100. PubMed ID: 29621742
    [TBL] [Abstract][Full Text] [Related]  

  • 17. An island apart? Risks and prices in the Australian cryptomarket drug trade.
    Cunliffe J; Martin J; Décary-Hétu D; Aldridge J
    Int J Drug Policy; 2017 Dec; 50():64-73. PubMed ID: 29055855
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Forensic drug intelligence and the rise of cryptomarkets. Part I: Studying the Australian virtual market.
    Broséus J; Morelato M; Tahtouh M; Roux C
    Forensic Sci Int; 2017 Oct; 279():288-301. PubMed ID: 28927690
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Nonmedical prescription psychiatric drug use and the darknet: A cryptomarket analysis.
    Cunliffe J; Décary-Hêtu D; Pollak TA
    Int J Drug Policy; 2019 Nov; 73():263-272. PubMed ID: 30772109
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Who sells what? Country specific differences in substance availability on the Agora cryptomarket.
    Van Buskirk J; Naicker S; Roxburgh A; Bruno R; Burns L
    Int J Drug Policy; 2016 Sep; 35():16-23. PubMed ID: 27520115
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.